CA2864040A1 - Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use - Google Patents
Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use Download PDFInfo
- Publication number
- CA2864040A1 CA2864040A1 CA2864040A CA2864040A CA2864040A1 CA 2864040 A1 CA2864040 A1 CA 2864040A1 CA 2864040 A CA2864040 A CA 2864040A CA 2864040 A CA2864040 A CA 2864040A CA 2864040 A1 CA2864040 A1 CA 2864040A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical compositions
- methods
- morpholinoalkyl
- disease
- fumarate compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261595835P | 2012-02-07 | 2012-02-07 | |
US61/595,835 | 2012-02-07 | ||
PCT/US2013/025118 WO2013119791A1 (en) | 2012-02-07 | 2013-02-07 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2864040A1 true CA2864040A1 (en) | 2013-08-15 |
Family
ID=47720772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2864040A Abandoned CA2864040A1 (en) | 2012-02-07 | 2013-02-07 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
Country Status (15)
Country | Link |
---|---|
US (2) | US8952006B2 (en) |
EP (1) | EP2812319A1 (en) |
JP (1) | JP5918395B2 (en) |
KR (1) | KR20140129136A (en) |
CN (1) | CN104169261A (en) |
AU (1) | AU2013203335B2 (en) |
BR (1) | BR112014019480A8 (en) |
CA (1) | CA2864040A1 (en) |
IL (1) | IL233941A0 (en) |
MX (1) | MX2014009511A (en) |
NZ (1) | NZ629728A (en) |
RU (1) | RU2014136394A (en) |
TW (1) | TWI486339B (en) |
WO (1) | WO2013119791A1 (en) |
ZA (1) | ZA201406145B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10080733B2 (en) | 2013-03-14 | 2018-09-25 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11230548B2 (en) | 2013-03-14 | 2022-01-25 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2477884T3 (en) | 2008-08-19 | 2014-07-18 | Xenoport, Inc. | Methyl hydrogen hydrogen fumarate prodrugs, pharmaceutical compositions thereof and methods of use |
WO2013181451A1 (en) * | 2012-05-30 | 2013-12-05 | Xenoport, Inc. | Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate |
CA2882730C (en) * | 2012-08-22 | 2019-12-31 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
CA2882713A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
WO2014031901A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of use for monomethyl fumarate and prodrugs thereof |
TW201436790A (en) * | 2012-12-21 | 2014-10-01 | Biogen Idec Inc | Deuterium substituted fumarate derivatives |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
TW201516020A (en) | 2013-09-06 | 2015-05-01 | Xenoport Inc | Crystalline forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
EP3049074A1 (en) * | 2013-09-27 | 2016-08-03 | ratiopharm GmbH | Prodrugs of monomethyl fumarate (mmf) |
WO2015082590A2 (en) * | 2013-12-05 | 2015-06-11 | Ratiopharm Gmbh | Bis-mmf derivatives |
ES2753361T3 (en) * | 2014-02-24 | 2020-04-08 | Alkermes Pharma Ireland Ltd | Sulfonamide and sulfinamide fumarate prodrugs and their use in the treatment of various diseases |
EP3119791B1 (en) | 2014-03-21 | 2019-01-16 | Université Paris-Est Créteil Val de Marne | Fumarate-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
US10170537B2 (en) | 2014-12-23 | 2019-01-01 | International Business Machines Corporation | Capacitor structure compatible with nanowire CMOS |
US9630934B2 (en) * | 2015-02-08 | 2017-04-25 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
CN115957294A (en) | 2015-05-28 | 2023-04-14 | 贝勒医学院 | Beneficial effects of supplementation with N-acetylcysteine and glycine to improve glutathione levels |
CN111065619B (en) * | 2017-08-29 | 2022-08-12 | 浙江海正药业股份有限公司 | (E) -alpha, beta-unsaturated amide compound, preparation method and application thereof |
CN116307280B (en) * | 2023-05-18 | 2023-08-01 | 成都理工大学 | Quantitative evaluation method for sulfur blockage damage of reservoir of acid gas reservoir |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2163060A1 (en) * | 1971-12-18 | 1973-06-20 | Basf Ag | Aqueous DISPERSIONS OF MIXED POLYMERIZES OF MONOESTERS OF UNSATURATED DICARBONIC ACIDS |
DE19721099C2 (en) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Use of fumaric acid derivatives |
DE19814358C2 (en) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn |
DE19839566C2 (en) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Use of fumaric acid derivatives in transplant medicine |
DE19848260C2 (en) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumaric microtablets |
DE19853487A1 (en) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
DE10000577A1 (en) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity |
DE10101307A1 (en) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumaric acid derivatives as NF-kappaB inhibitor |
RU2290946C2 (en) | 2001-01-12 | 2007-01-10 | Фумафарм Аг | Fumaric acid amides |
DE10217314A1 (en) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclic and oxacarboncyclic fumaric acid oligomers |
GB0320441D0 (en) * | 2003-09-02 | 2003-10-01 | Givaudan Sa | Organic compounds |
MXPA06002657A (en) | 2003-09-09 | 2006-06-05 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma. |
DE10342423A1 (en) | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage |
EP2801354B1 (en) | 2004-10-08 | 2017-02-08 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US20080004344A1 (en) | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
DE102005022845A1 (en) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiosuccinic acid derivatives and their use |
WO2007042034A1 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
CN101304732A (en) * | 2005-10-07 | 2008-11-12 | Adi技术制药股份公司 | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
AU2007248473B2 (en) | 2006-05-05 | 2011-01-27 | The Regents Of The University Of Michigan | Bivalent Smac mimetics and the uses thereof |
ES2477884T3 (en) * | 2008-08-19 | 2014-07-18 | Xenoport, Inc. | Methyl hydrogen hydrogen fumarate prodrugs, pharmaceutical compositions thereof and methods of use |
WO2011085211A1 (en) * | 2010-01-08 | 2011-07-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid fumarate derivatives and their uses |
EP2934507B1 (en) | 2012-12-21 | 2017-05-31 | ratiopharm GmbH | Prodrugs of monomethyl fumarate (mmf) |
-
2013
- 2013-02-07 TW TW102104764A patent/TWI486339B/en not_active IP Right Cessation
- 2013-02-07 KR KR20147025151A patent/KR20140129136A/en active IP Right Grant
- 2013-02-07 BR BR112014019480A patent/BR112014019480A8/en not_active IP Right Cessation
- 2013-02-07 JP JP2014556656A patent/JP5918395B2/en not_active Expired - Fee Related
- 2013-02-07 CA CA2864040A patent/CA2864040A1/en not_active Abandoned
- 2013-02-07 EP EP13704701.5A patent/EP2812319A1/en not_active Withdrawn
- 2013-02-07 NZ NZ629728A patent/NZ629728A/en not_active IP Right Cessation
- 2013-02-07 MX MX2014009511A patent/MX2014009511A/en unknown
- 2013-02-07 AU AU2013203335A patent/AU2013203335B2/en not_active Ceased
- 2013-02-07 US US13/761,864 patent/US8952006B2/en not_active Expired - Fee Related
- 2013-02-07 CN CN201380014174.7A patent/CN104169261A/en active Pending
- 2013-02-07 WO PCT/US2013/025118 patent/WO2013119791A1/en active Application Filing
- 2013-02-07 RU RU2014136394A patent/RU2014136394A/en not_active Application Discontinuation
- 2013-08-14 US US13/967,283 patent/US20140051705A1/en not_active Abandoned
-
2014
- 2014-08-04 IL IL233941A patent/IL233941A0/en unknown
- 2014-08-21 ZA ZA2014/06145A patent/ZA201406145B/en unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10080733B2 (en) | 2013-03-14 | 2018-09-25 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US10406133B2 (en) | 2013-03-14 | 2019-09-10 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US10596140B2 (en) | 2013-03-14 | 2020-03-24 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11083703B2 (en) | 2013-03-14 | 2021-08-10 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11230548B2 (en) | 2013-03-14 | 2022-01-25 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11679092B2 (en) | 2013-03-14 | 2023-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11905298B2 (en) | 2013-03-14 | 2024-02-20 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
Also Published As
Publication number | Publication date |
---|---|
JP5918395B2 (en) | 2016-05-18 |
EP2812319A1 (en) | 2014-12-17 |
US20130203753A1 (en) | 2013-08-08 |
NZ629728A (en) | 2016-07-29 |
US20140051705A1 (en) | 2014-02-20 |
IL233941A0 (en) | 2014-09-30 |
MX2014009511A (en) | 2014-10-24 |
BR112014019480A2 (en) | 2017-06-20 |
ZA201406145B (en) | 2016-06-29 |
BR112014019480A8 (en) | 2017-07-11 |
WO2013119791A1 (en) | 2013-08-15 |
AU2013203335B2 (en) | 2016-05-26 |
TW201343634A (en) | 2013-11-01 |
AU2013203335A1 (en) | 2013-08-22 |
CN104169261A (en) | 2014-11-26 |
KR20140129136A (en) | 2014-11-06 |
TWI486339B (en) | 2015-06-01 |
US8952006B2 (en) | 2015-02-10 |
RU2014136394A (en) | 2016-03-27 |
JP2015508073A (en) | 2015-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2864040A1 (en) | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | |
HK1258231A1 (en) | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders | |
IL279359B1 (en) | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders | |
EP3359662A4 (en) | Compositions and methods for treating huntington's disease and related disorders | |
IL257581A (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
MX2014007254A (en) | Pharmaceutical compositions comprising glitazones and nrf2 activators. | |
ZA201405401B (en) | Neuroactive steroid formulations and methods of treating cns disorders | |
IL225239A0 (en) | Compositions for the treatment of acne and related disorders | |
EP2911664A4 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
ZA201502597B (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
HK1198909A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
HK1213912A1 (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
EP3377118A4 (en) | Methods for treating alzheimer's disease and related disorders | |
WO2012027482A3 (en) | Compounds, compositions and methods related to ppar antagonists | |
WO2016199170A3 (en) | Paliperidone palmitate particles and compositions thereof | |
NZ702239A (en) | Heteroaryl compounds and methods of use thereof | |
MX2016000724A (en) | Ppar-sparing compounds for the treatment of metabolic diseases. | |
EP3475299A4 (en) | Compounds useful to treat metabolic disorders | |
FR3007405B1 (en) | PROCESS FOR THE PREPARATION OF A COMPOSITION COMPRISING FUNCTIONALIZED SILICO / GERMANO-METALLIC PARTICLES AND COMPOSITION OBTAINED | |
WO2016059269A8 (en) | Compounds derived from 3-alkylamino-1h-indole acrylate, and the use thereof in the treatment of neurodegenerative diseases | |
IL234616A0 (en) | Herbal composition for the treatment of metabolic disorders | |
ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
WO2014015153A3 (en) | Treating ewing's sarcoma and ews-fli1 related disorders | |
EP3138567A4 (en) | Pharmaceutical composition for treating chronic obstructive pulmonary diseases | |
WO2016150451A2 (en) | Economical and environmentally-friendly mixture for increasing the octane rating from 80 to 90 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140806 |
|
FZDE | Discontinued |
Effective date: 20171128 |